

Claim 10, line 1; change "tumours" to -- tumors --.

Claim 10, line 2; change "antitumourally" to -- antitumorally --.

Claim 11, last line; change "tumours" to -- tumors --.

Claim 12, last line; change "tumours" to -- tumors --.

Claim 13, line 2; change "antitumourally" to -- antitumorally --.

Claim 13, Page 90, last line; change "tumour" to -- tumor --.

REMARKS

By the foregoing amendments to the specification and claims, the text has been Americanized and editorial errors noted have been corrected. The only changes deemed worthy of comment are: 1) the amending of line 12 on Page 50 which corrects the identity of one of the starting materials in Example 22; and 2) the amending of line 23 on Page 63 which corrects the identity of the compound of Example 68.


In compliance with the duty of disclosure set forth in 37 CFR 1.56, the Examiner's attention is respectfully invited to all of the references that are listed on the enclosed completed PTO-1449 form. A copy of each of said references is also enclosed. In this connection, it should be noted that USP 4,853,386 is the U.S. equivalent of European Patent 212,535. In addition, since WO 97/20842 is not in the English language, its corresponding Chemical Abstracts and Derwent Abstract references are also enclosed.

Although this Second Preliminary Amendment and Citation of Prior Art is being filed more than three months from the 35 USC 371 date, it is being filed prior to receipt of a first Office Action and, therefore, no additional fee is deemed to be necessitated by making the relevant prior art of record at this time. However, on the chance that this Second Preliminary Amendment and Citation of Prior Art crosses in the mail with a first Office Action that bears a

date prior to the date of this Second Preliminary Amendment and Citation of Prior Art (the benefit of which Applicants are entitled to by virtue of the "Certificate of Mailing" stamp on Page 1 thereof), please charge the \$240.00 fee required by 37 CFR 1.97(c) to Deposit Account No. 19-0134.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6921



Joseph U. Borovian
Agent for Applicants
Reg. No. 26,631

JJB:mjl

Encls.: Copy of completed PTO-1449 form
Copies of all references listed on the
PTO-1449 form
Postcard

Date: November 8, 1999